Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa vs short-acting rHuEPO for hemoglobin control in maintenance hemodialysis
ChiCTR2500096455Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of darbepoetin alfa and epoetin alfa in anemia of renal disease and Uraemic Anaemia (2 cohorts), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Hemoglobin level at 40-52 weeks. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
darbepoetin alfaepoetin alfa
03
Conditions
anemia of renal diseaseUraemic Anaemia
Beyond the preview
Go deeper on ChiCTR2500096455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096455.